Cargando…

de Novo TINF2 C.845G>A: Pathogenic Variant in Patient with Dyskeratosis Congenita

Dyskeratosis congenita (DC) is a clinically and genetically heterogeneous, multisystem inherited syndrome with a very high risk for bone marrow failure (BMF) and cancer predisposition. The classical clinical form of DC is characterized by abnormal skin pigmentation, nail dystrophy, and oral leukopla...

Descripción completa

Detalles Bibliográficos
Autores principales: Kocheva, SA, Gjorgjievska, M, Martinova, K, Antevska-Trajkova, Z, Jovanovska, A, Plaseska-Karanfilska, D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sciendo 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524180/
https://www.ncbi.nlm.nih.gov/pubmed/36249522
http://dx.doi.org/10.2478/bjmg-2021-0027
_version_ 1784800450517663744
author Kocheva, SA
Gjorgjievska, M
Martinova, K
Antevska-Trajkova, Z
Jovanovska, A
Plaseska-Karanfilska, D
author_facet Kocheva, SA
Gjorgjievska, M
Martinova, K
Antevska-Trajkova, Z
Jovanovska, A
Plaseska-Karanfilska, D
author_sort Kocheva, SA
collection PubMed
description Dyskeratosis congenita (DC) is a clinically and genetically heterogeneous, multisystem inherited syndrome with a very high risk for bone marrow failure (BMF) and cancer predisposition. The classical clinical form of DC is characterized by abnormal skin pigmentation, nail dystrophy, and oral leukoplakia. Bone marrow failure is considered to be an important and major complication of DC and the leading cause of death which develops in around 85% of cases. A number of genes involved in telomere maintenance are associated with DC, such as genes that encode the components of the telomerase complex (TERT, DKC1, TERC, NOP10, and NHP2), T-loop assembly protein (RTEL1), telomere capping (CTC1), telomere shelterin complex (TINF2), and telomerase trafficking protein (TCAB1). Mutations in TINF2 have been reported in 11–20% of all patients with DC and have been associated with bone marrow failure. Here we report on a 19-month old boy with very early presentation of bone marrow failure as a first clinical manifestation of DC. Upon first admission, the patient presented with thrombocytopenia and macrocytic anemia. Soon after, his blood counts deteriorated with the development of pancytopenia and aplastic anemia. Four months later, he developed nail dystrophy and skin hyperpigmentation. A de novo heterozygous pathogenic variant c.845G>A, p.(Arg282His) was located in exon 6 of TINF2 gene and was identified via clinical exome sequencing. The findings confirmed the diagnosis of DC. This is the first case with DC due to TINF2 pathogenic variant reported in North Macedonia.
format Online
Article
Text
id pubmed-9524180
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Sciendo
record_format MEDLINE/PubMed
spelling pubmed-95241802022-10-14 de Novo TINF2 C.845G>A: Pathogenic Variant in Patient with Dyskeratosis Congenita Kocheva, SA Gjorgjievska, M Martinova, K Antevska-Trajkova, Z Jovanovska, A Plaseska-Karanfilska, D Balkan J Med Genet Case Report Dyskeratosis congenita (DC) is a clinically and genetically heterogeneous, multisystem inherited syndrome with a very high risk for bone marrow failure (BMF) and cancer predisposition. The classical clinical form of DC is characterized by abnormal skin pigmentation, nail dystrophy, and oral leukoplakia. Bone marrow failure is considered to be an important and major complication of DC and the leading cause of death which develops in around 85% of cases. A number of genes involved in telomere maintenance are associated with DC, such as genes that encode the components of the telomerase complex (TERT, DKC1, TERC, NOP10, and NHP2), T-loop assembly protein (RTEL1), telomere capping (CTC1), telomere shelterin complex (TINF2), and telomerase trafficking protein (TCAB1). Mutations in TINF2 have been reported in 11–20% of all patients with DC and have been associated with bone marrow failure. Here we report on a 19-month old boy with very early presentation of bone marrow failure as a first clinical manifestation of DC. Upon first admission, the patient presented with thrombocytopenia and macrocytic anemia. Soon after, his blood counts deteriorated with the development of pancytopenia and aplastic anemia. Four months later, he developed nail dystrophy and skin hyperpigmentation. A de novo heterozygous pathogenic variant c.845G>A, p.(Arg282His) was located in exon 6 of TINF2 gene and was identified via clinical exome sequencing. The findings confirmed the diagnosis of DC. This is the first case with DC due to TINF2 pathogenic variant reported in North Macedonia. Sciendo 2022-06-05 /pmc/articles/PMC9524180/ /pubmed/36249522 http://dx.doi.org/10.2478/bjmg-2021-0027 Text en © 2021 SA Kocheva et al., published by Sciendo https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
spellingShingle Case Report
Kocheva, SA
Gjorgjievska, M
Martinova, K
Antevska-Trajkova, Z
Jovanovska, A
Plaseska-Karanfilska, D
de Novo TINF2 C.845G>A: Pathogenic Variant in Patient with Dyskeratosis Congenita
title de Novo TINF2 C.845G>A: Pathogenic Variant in Patient with Dyskeratosis Congenita
title_full de Novo TINF2 C.845G>A: Pathogenic Variant in Patient with Dyskeratosis Congenita
title_fullStr de Novo TINF2 C.845G>A: Pathogenic Variant in Patient with Dyskeratosis Congenita
title_full_unstemmed de Novo TINF2 C.845G>A: Pathogenic Variant in Patient with Dyskeratosis Congenita
title_short de Novo TINF2 C.845G>A: Pathogenic Variant in Patient with Dyskeratosis Congenita
title_sort de novo tinf2 c.845g>a: pathogenic variant in patient with dyskeratosis congenita
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524180/
https://www.ncbi.nlm.nih.gov/pubmed/36249522
http://dx.doi.org/10.2478/bjmg-2021-0027
work_keys_str_mv AT kochevasa denovotinf2c845gapathogenicvariantinpatientwithdyskeratosiscongenita
AT gjorgjievskam denovotinf2c845gapathogenicvariantinpatientwithdyskeratosiscongenita
AT martinovak denovotinf2c845gapathogenicvariantinpatientwithdyskeratosiscongenita
AT antevskatrajkovaz denovotinf2c845gapathogenicvariantinpatientwithdyskeratosiscongenita
AT jovanovskaa denovotinf2c845gapathogenicvariantinpatientwithdyskeratosiscongenita
AT plaseskakaranfilskad denovotinf2c845gapathogenicvariantinpatientwithdyskeratosiscongenita